Thiazolidinedione (Pioglitazone) Blocks P. gingivalis - and F. nucleatum,but not E. coli,Lipopolysaccharide (LPS)-induced Interleukin-6 (IL-6) Production in Adipocytes

Abstract

An elevated level of C-reactive protein (CRP) predicts the future development of coronary heart disease. Periodontitis appears to up-regulate CRP. CRP is produced by hepatocytes in response to interleukin-6 (IL-6). A major source of IL-6 in obese subjects is adipocytes. We hypothesized that lipopolysaccharide (LPS) from periodontal pathogens stimulated adipocytes to produce IL-6, and that the production was suppressed by the drugs targeted against insulin resistance, thiazolidinedione (pioglitazone), since this agent potentially showed an anti-inflammatory effect. Mouse 3T3-L1 adipocytes were stimulated with E. coli, P. gingivalis, and F. nucleatum LPS. The IL-6 concentration in culture supernatants was measured. All LPS stimulated adipocytes to produce IL-6. Although pioglitazone changed adipocyte appearance from large to small, and completely suppressed P. gingivalis and F. nucleatum LPS-induced IL-6 production, E. coli LPS-induced IL-6 production was not efficiently blocked. Thus, pioglitazone completely blocked periodontal-bacteria-derived LPS-induced IL-6 production in adipocytes, a major inducer of CRP.

Get full access to this article

View all access options for this article.

References

Bainbridge BW, Darveau RP (2001). Porphyromonas gingivalis lipopolysaccharide: an unusual pattern recognition receptor ligand for the innate host defense system. Acta Odontol Scand 59:131–138.

Beck JD, Offenbacher S, Williams R, Gibbs P, Garcia R (1998). Periodontitis: a risk factor for coronary heart disease? Ann Periodontol 3:127–141.

Bernlohr DA, Angus CW, Lane MD, Bolanowski MA, Kelly TJ Jr (1984). Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci USA 81:5468–5472.

Bierman EL (1992). George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 12:647–656.

Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. (1998). Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273:25573–25580.

Coppack SW (2001). Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349–356.

Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454.

Iwamoto Y, Nishimura F, Soga Y, Takeuchi K, Kurihara M, Takashiba S, et al. (2003). Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor necrosis factor-alpha, but not adiponectin levels in patients with chronic periodontitis. J Periodontol 74:1231–1236.

Lin Y, Lee H, Berg AH, Lisanti MP, Shapiro L, Scherer PE (2000). The lipopolysaccharide-activated Toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 275:24255–24263.

10.

Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U (2000). Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol 71:1528–1534.

11.

Nishimura F, Taniguchi A, Iwamoto Y, Soga Y, Fukushima M, Nagasaka S, et al. (2002). Porphyromonas gingivalis infection is associated with elevated C-reactive protein in nonobese Japanese type 2 diabetic subjects. Diabetes Care 25:1888.

12.

Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E (2001). Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol 72:1221–1227.

13.

Oates JC, Reilly CM, Crosby MB, Gilkeson GS (2002). Peroxisome proliferators-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum 46:598–605.

14.

Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al. (1998). Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354–1361.

15.

Onoue S, Imai T, Kumada H, Umemoto T, Kaca W, Isshiki Y, et al. (2003). Serum antibodies of periodontitis patients compared to the lipopolysaccharides of Porphyromonas gingivalis and Fusobacterium nucleatum. Microbiol Immunol 47:51–55.

16.

Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P (2003). C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 21:1787–1803.

17.

Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79–82.

18.

Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997). Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979. Erratum in N Engl J Med 337:356, 1997.

19.

Ruan H, Pownall HJ, Lodish HF (2003). Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem 278:28181–28192.

20.

Salvi GE, Collins JG, Yalda B, Arnold RR, Lang NP, Offenbacher S (1997). Monocytic TNF alpha secretion patterns in IDDM patients with periodontal diseases. J Clin Periodontol 24:8–16.

21.

Slade GD, Offenbacher S, Beck JD, Heiss G, Pankow JS (2000). Acute-phase inflammatory response to periodontal disease in the US population. J Dent Res 79:49–57.

22.

Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997). Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610–614.

23.

Willson TM, Lambert MH, Kliewer SA (2001). Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70:341–367.

24.

Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, et al. (2002). Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105:804–809.